Clinical Trial Update: Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. [Phase 3]

View source ↗

Summary

Phase 3 safety-focused trial comparing the DTaP-IPV-Hep B-PRP~T vaccine to Tritanrix-HepB/Hib and OPV when given at 2, 4, and 6 months.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Tetanus

Drugs mentioned

• DTaP-IPV-Hep B-PRP-T
• OPV (Oral polio vaccine)
• Tritanrix-HepB/Hib

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2012-11-19